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1. IntroductIon
The era of recombinant therapeutics production initially 
started with E. coli still being successful only with the simple 
proteins like insulin, growth hormones that are not glycosylated 
and or that, while glycosylated in their native form, do not 
require glycosylation to exert pharmacological activity (such 
as IFN-α, IFN-β, IFN-γ, interleukin-2)1. Rather than E.coli 
yeast system (Pichiapastoris and Saccharomyces) specifically 
employed for producing glyco protein but some of those 
were hyper antigenic may not be suitable for the therapeutic 
purpose2,3. Most of the human protein are glyco protein and 
needs glycosylation for their proper function. Mammalian 
cell culture system is commonly used for the production 
of the glycoprotein. For the production of more complex 
proteins requiring post-translational modifications (like 
glycosylation–addition of carbohydrate moiety to the protein) 
the Chinese hamster ovary (CHO) cells, baby hamster kidney 
(BHK) cells, mouse myeloma cell lines were mainly used and 
commercialised. The main advantage of this is the glyco protein 
produced is not immunogenic in human or animal4-8. However, 
this is a very expensive system for production of recombinant 
protein. Both the microbial and mammalian cell culture system 
is expensive to process that requires huge capital investment, 
trained main power to operate the system and operation cost 
is high thereby increasing the cost of the recombinant protein 
produced that is being commercialised9-13. 
This is an entry point where the plant’s systems were 
recognised for their simple growth requirements, the advantage of 
post-translational modification, scalability, targeted approach for 
organ/sub cellular compartments. The plant is a cheap alternative 
for the production of the recombinant protein. It requires less 
capital investment and scale up can be easily done in the case of 
requirement. It is estimated that the plant-derived recombinant 
protein can be 10-20 fold less expensive than the fermenter based 
recombinant protein production. Also, the initial investment 
for the establishment is less and scale up is possible since it is 
following simple plant grower’s strategies for mass propagation. 
Hence, the focus protein therapeutics production in the bacterial 
and mammalian systems is slightly moved to plant genetic 
engineering based technique called ‘Plant Molecular Pharming’. 
The inherent potential of plant system for protein production is 
the striking phenomenon led researcher’s attentions to overcome 
the bottlenecks in the existing system are in routine practice. The 
most appropriate substitute is planted molecular farming since 
it is free from animal pathogen contamination risks, more yield 
percentage and economic. Since plants have long been used for 
the production of many protein therapeutics, there are many 
shortcomings affect the plant produced protein therapeutics to 
meet commercialisation standards. Recent developments in the 
plant molecular farming especially the development of simplest 
protein purification strategies, deconstructed viral vectors, glyco 
engineering and magnifection technology12,14-23 were the most 
astonishing developments added more value to the plant-based 
therapeutics that are already commercialised and in various 
phases of clinical trials.
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2. PlAntS AS A ProteIn ProductIon 
hoSt
Plant cells are versatile by means of combining the 
advantages of post-translational modification, simplicity and 
economic requirements for scale-up and obligatorily free 
from potential animal pathogen contamination. Heterologous 
protein expression and its stable functionality may give success 
in the bacterial system, but in most of the cases, plasmid 
instability and proteolytic degradation in the system makes it 
is unfeasible to commercialise the recovered product24. Plant 
biopharming is the boon for such conditions, to express the 
grams of functional proteins per kilogram of biomass. Several 
studies have proven that product recovery is simple, rapid and 
devoid of pyrogens. 
2.1 conventional Approaches
Plant cells can be cultivated under in-vitro conditions by 
hairy root, shootyteratomas, immobilised cells and suspension 
cell cultures. So, when compared to all these techniques cell 
suspension culture is of a greater advantage because they are 
amenable to GMP procedures and can be cultivated in large-
scale using bioreactors25. Several plant species are used for 
suspension cultures; the most commonly used ones are the 
domestic crops including tobacco, rice, alfalfa, tomato and 
soybean. Among this tobacco cultivar bright yellow (BY-2) and 
Nicotianatobacum 1 (NT-1) are used for recombinant protein 
production26,27. The increased production of recombinant 
proteins in the cell suspension culture can be achieved by the 
use of a suitable promoter, signal sequence and a terminator. 
Hence, the recombinant proteins that are produced in large-
scale can be obtained by downstream processing.
The production of pharmaceutical proteins using 
transgenic plants has also gained some attention over the last 
decade. Here the stable transgenic plants are produced by 
means of agrobacterium –based vector-mediated gene transfer. 
Using this approach a whole range of therapeutic proteins has 
been produced in the plant tissue. Depending upon the use of 
a specific promoter, expression can be achieved uniformly 
throughout the plant or it can be limited up to the expression 
in plant seed, organs and sub-cellular organelles28–33. Apart 
from this, the focus of future research is in the production 
of oral vaccines in the edible plants/ fruits, such as tomatoes 
and bananas. This particular approach is elegant by which 
the consumption of plant materials provides an inexpensive, 
efficient and technically straightforward mode of large –scale 
vaccine delivery, particularly in poorer world regions. Since 
the generation of the stable transgenic plant for the production 
of recombinant protein is a time-consuming process transient 
mode expression has been adapted to produce proteins in large 
scale.
2.2 Plant biopharming concept
Plant biopharming follows plant grower strategies to 
propagate plants. Plant molecular farming method involves 
the use of disarmed strains of agrobacterium tumifaciens 
employed for introducing recombinant plasmids into the plant 
intracellular spaces through syringe infiltration or vacuum 
infiltration techniques. This results in ectopic integration into 
the plant genome. Gene expression occurs 3-5 days of post 
infiltration immediately. This comeback is rooted from the 
perception that the usage of plant-based products is the safer 
and holistic approach. 
Transient expression is feasible to produce a lot of 
proteins by using high expression vectors. Agroinfiltration 
is one of the most widely used techniques for transient gene 
expression initially known for host-virus interaction studies. 
Agroinfiltration followed by expression studied within a short 
period of time and can be assayed directly without any complex 
steps or time consuming procedures34. The basic protocol for the 
production of protein therapeutics in plant system comprising 
the three major steps, 
(a)  Construction of plant expression vector
(b)  Host selection, and 
(c)  Agroinfiltration of recombinant constructs into the 
production host plant.
 
2.2.1 Construction of Plant Expression vector
The expression constructs, design, determines the level 
of transcription and translation of the heterologous genes in 
the different species. Optimised factors for the transcription, 
translation, post-translational events and gene regulatory 
elements incorporated into the vectors achieve redress 
expression of the desired protein. Genes, those originally 
designed for the bacterial system is simply got modified to 
shuttle in the plant system by the addition of legumin signal 
peptide35. To improve the intracellular stability and yield 
percentage KDEL motif is incorporated into the sequence, 
which translocates the sequence into ER24,36,37. Irrespective of 
tissues constitutive promoters transcribe the genes effectively; 
this may be either good enough for monocotyledon and 
dicotyledonous plants. Largely CaMV35S has been used as a 
strong constitutive promoter for the PT production in dicots, 
for monocots ubiquitin-1 promoter38. A study compared 
CaMV 35S, subterranean clover stunt virus (SCSV), segment 
4 (S4) promoter element and double promoter (S4S4) promoter 
efficiency in three different plant expression system, among 
these three CaMV35 leads the expression actually than S4, 
and even S4:S4, further it proves the theoretical potential 
of producing 153 μg/g24. The highest level of 2% TSP was 
achieved by expressing the α-trichosanthin gene under the 
transcriptional control of tobamovirussubgenomic promoter 
in the plant viral RNA vector39. Hence, plant viral vectors 
serve as an excellent carrier for the expression of multi-unit 
proteins like antibodies and it is more rapid as compared to 
the bacterial vectors, where regeneration after transformation, 
hardening and sexual crossing of plants to achieve 
multiple subunit assemblies are a highly time-consuming 
process40. Further improvement has made in the viral vector 
construction by following deconstructive approach and 
designed the novel, high expression vector system combines 
the advantages of viral vectors and non-viral vector systems 
called ‘Magnifection technology’18,29,41. This scenario is most 
beneficial in many aspects by using agrobacterium as an 
infective agent, high expression levels of viral vectors by 
incorporating viral regulation accessories, post-translational 
modification and simple growth requirements of plants.
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2.2.2 Host Selection
Host selection is the important parameter which reinforces 
the absolute yield of the recombinant protein in the transgenic 
plants. Tobacco was the first plant to express a recombinant 
antibody in 1988. Several reports show the potentiality of 
the use of various plants such as Nicotianatabaccum and N. 
benthamiana, cereals (rice, wheat, maize), legumes (pea, 
soybean, alfalfa), leafy vegetables (Lettuce and Amaranthus, 
Spinach, Alfalfa) and fruit and root crops (tomato, potato).
Before making a choice, the requirement has to be 
customised as to reduce the production and storage cost. For 
instance, targeted expression of antibodies in potato tubers 
and barely seeds enhances the intracellular stability further it 
can be stored even at room temperature and reduces the post-
harvest storage24 cost, if the antibody is expressed in the leaves 
has to be stored and transported in frozen condition to maintain 
the stability of the protein. Selection of less maintenance, easy 
growing crop, minimises the production cost. Apart from this 




Agroinfiltration is the technique used to study the plant-
pathogen interaction, but now the technique has been adapted 
to study transient gene expression. Simply, the recombinant 
plasmid carrying agrobacterium culture is introduced into the 
intracellular spaces of the leaves by making a small nick in the 
abaxile side of the leaf tissue or through the stomatal openings. 
The agro solution is injected into the leaf by placing the tip of 
the needless syringe in the leaf and simultaneously applying 
gentle counter pressure to the other side of the leaf (Fig. 1). 
The agrobacterium solution will spread into the air spaces 
inside the leaf. Another way of introducing agrobacterium 
cultures into leaf intracellular spaces by applying vacuum 
pressure. Vacuum infiltration is often used in labs to scale-up 
agroinfiltration for the production of test batches of protein. In 
vacuum infiltration, the plant tissue/leaf disk/the whole plantlet 
is submerged into the a. tumefaciens culture and subjected to 
decreased pressure followed by rapid re-pressurisation (Fig. 
2). By vacuum infiltration, almost all the parts of the leaf 
are infected by agrobacterium and also this is the preferable 
method for the large-scale production of proteins in various 
plant species, such as lettuce and Arabidopsis that are not 
amenable for syringe infiltration. Agroinfiltrated plants were 
maintained in optimal condition for 4-6 days and followed 
by downstream processing of infiltrated tissues, which 
includes homogenisation harvested leaf tissues (4-6 days of 
post infiltration (dpi)), column purification either in native/
denaturing conditions, dialysis of purified fractions to remove 
excess salts, concentration and the plant produced protein 
function is confirmed further by western blotting and other 
functional assays.
3. rAPId ProductIon of therAPeutIcS 
durIng ePIdemIc/PAndemIc 
emergency
Pandemic (an epidemic disease spread over an ample 
region)/epidemic are sudden outbreak of a disease causing 
widespread and mass destruction within a short period of 
time. The epidemic/pandemic diseases are considered as a 
global threat that accounts for about >60 per cent human 
illness42, especially the countries with more diversity and huge 
population are at high risk. Therefore pandemic/epidemic 
planning and preparedness is necessary to reduce transmission 
of the pathogenic strain, to control hospitalisations, deaths 
Figure 2.  Vacuum infiltration technique: (a) Plant preparation 
for agroinfiltration, (b) the plant is immersed in 
the Agrobacterium solution in the vacuum chamber, 
(c) Vacuum infiltration setup, (d) After vacuum re-
pressurisation the plant is infiltrated and carefully 
removed from the chamber, (e) completely vacuum 
infiltrated plant, and (f) Infiltrated leaf after 4 dpi.
(a) (b) (c)
(d) (e) (f)
Figure 1. Syringe infiltration technique and GFP expression 
in leaves observed under UV light after 4 days 
of post infiltration; (a) N. benthamiana seedlings, 
(b) Propagation of N. benthamiana plantlets in plant 
containment room, (c) Well grown plantlet, (d)(e) and 
(f) Syringe infiltration of pEAQ-GFP construct into 
the abaxial side of the leafs, and (g) GFP expression 





IyAPPAN, et al.: DEF. LIFE SCI. J., VOL. 2, NO. 2, APRIL 2017, DOI : 10.14429/dlsj.2.11372
and to maintain essential services to reduce the economic and 
social impact of the pandemic outbreaks. Even though, we 
experienced many unforeseeable outbreaks like Chikungunya, 
Ebola and zika over proper pandemic planning. Chikungunya 
and Swine flu is a good example could describe the real 
difficulties we faced during recent outbreaks. This indicates 
still we need to explore, adapt and develop technologies to 
produce diagnostics and therapeutics in rapid manner to 
meet the demand in pandemic emergencies. Plant molecular 
farming one such convenient technology to adapt easily 
without huge investment to produce tons of doses rapidly. 
Plant molecular farming approach is most extensively 
used and it allows for the production of proteins in large 
quantities within a short time frame, this is particularly an 
attractive feature in case of pathogens that may be used for 
bioweapons and for epidemics43. Hence, plant-based vaccines 
that are transiently produced are with the native immunogenic 
properties stimulating both humoral and mucosal immune 
response44.Many industries like Medicago, Fraunhofer Center 
for Molecular Biotechnology/iBio, Fraunhofer IME, Icon 
Genetics, VAXX and Mapp Biopharmaceutical/LeafBio were 
the pioneer in plant based therapeutics productions. Medicago 
and Fraunhofer Center for Molecular Biotechnology/iBiohas 
developed virus like particles for vaccination against H1N1 and 
H5N1 within three weeks of receiving sequence information45-
47.MappBiophamaceutical Inc., a USA based company has 
produced a drug in tobacco leaves called ZMapp, which has 
been used to combat Ebola virus outbreak in Africa. Middle 
East respiratory syndrome corona virus (MERS-CoV) is an 
emerging pandemic disease. Due to its high mortality rate 
Product disease Plant Status
Vaccine
VLPs50 Blue tongue virus (BTV) Nicotiana Benthamiana -
VP6 gene42 Rotavirus Chenopodium leaves On market
DPP4-Fc48 Middle east respiratory syndrome corona 
virus (MERS-CoV)
Tobacco -
hE1651,52 West Nile Nicotianabenthamiana On market
PA83 and DIV53 Anthrax Brown Mustard, Tobacco and Nicotianabenthamiana On market
vibrio cholera54 Cholera Rice and Potato Phase I
HA55 Influenza virus (H5N1) Nicotiana Benthamiana Phase I
HA56 Influenza virus (H1N1; 2009 pandemic) Nicotiana Benthamiana Phase I
Hepatitis B antigen (HBsAg)54 Hepatitis B Lettuce and potato Phase I and Phase II
Antiviral (griffithsin)57
Severe acute respiratory syndrome 
(SARS)
Nicotianabenthamiana On market
F1–LcrV fusion58 Plague Tomato, Tobacco and Nicotianabenthamiana On market
B559 Small pox Tobacco andNicotianabenthamiana On market
Capsid protein60 Norovirus Potato Phase I
LTB60 Enterotoxigenic E. coli Potato Phase I
HA (H7; VLP) Influenza virus (H7N9) Nicotiana Benthamiana Phase I
HA (VLP) (seasonal;
quadrivalent)
Influenza virus Nicotiana Benthamiana Phase I
Antibodies
Antibody against hepatitis B54 Vaccine purification Tobacco On market
CaroRX54 Dental caries Tobacco EU approved as medical advice
DoxoRX54 Side-effects of cancer therapy Tobacco Phase I completed
Fv antibodies54 Non-Hodgkin’s Lymphoma Tobacco Phase I
IgG (ICAM1)54 Common cold Tobacco Phase I
RhinoRX54 Common cold Tobacco Phase I completed
table 1. current status of plant derived therapeutics developed against epidemic/pandemic diseases
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it caused panic in South Korea during 2015 and currently, 
no effective drugs are available to treat this disease. Plant 
Biotechnology Inc a USA based company produced an 
immunoadhesion (DPP4-Fc) in transgenic tobacco plants. 
DPP4-Fc strongly binds with MERS-CoV and it prevents 
the virus from infecting the lung cells48. Keeping in view 
the practical need of new technology for the production and 
delivery of inexpensive vaccines, especially in the developing 
country like India plant derived vaccines is the best option in 
hand to combat pandemic diseases.
4. ChAllEnGES to oVErComE
Post-translational modification (PTM) is the major road 
block in the commercialisation of the plant based protein 
therapeutics, even though it has many ethical issues regarding 
environmental concerns about the transgene containment, 
antibiotic resistance, food safety and so on. Such regulatory 
hurdles can be easily overcome by good manufacturing 
practices (GMP) devised by the pharmaceutical industries. 
Still, PTM remains the daunting challenge to be tackled49.
The major technological challenge to be addressed by 
researchers is to ensure that the structure of the engineered 
protein results in functionality that is equivalent to that of 
the native form. Most human and other mammalian proteins 
are biochemically modified at their carboxy- and/or amino-
termini, and/or at the side chains of amino acids, during 
translation and post- translation events (covalent attachment 
of sugar chains i.e. glycosylation). Another challenge to 
researchers working on a suitable plant expression system for 
human therapeutics is inadequate information about a plant’s 
capacity to post-translationally modify human proteins, with 
glycosylation being a particular concern. Diverse glycoforms 
are rich in plant expression system as compared to the other 
mammalian expression system. Still,this is sufficient for 
the production functional antibodies in plant system where 
glycation is not affecting the confirmation and its function. 
More than half of the oligosaccharides N-linked to the 
plantibody have β (1,2)-xylose and α (1,3)-fucose residues 
linked to the core Man3GlcNAc2. Complex N-glycan 
structures were reported on the plantibody Guy’s 13; these 
structures were common in plant extracellular proteins. This 
is the evidence, which supports the antibody production in 
plant system is secreted and stored at the apoplast/vacuoles. 
Meanwhile, glycosylation is not anignorable modification in 
immunoproteins that happens during and after translation in 
amammalian system in order to provide resistance against 
protease cleavage, solubility and confers other physiochemical 
properties. Also, it performs some biological functions 
including antigenicity and immunogenicity.Plant system has 
altered glycans having β(1,2 )-xylose residue and α(1,3)-
fucose residues linked to the proximal N-acetylglucosamine, 
it is absent in animal system, this is how plant glycosylation 
collapse the function and lifetime of the protein therapeuticsin 
vivo38.Since the glycosylation pattern of plant and animal 
system has many differences, it has no effect on the antigen 
binding or specificity, and still, the immunogenicity and other 
concerns need to be addressed through developing inventions 
in glyco-engineering.
5. concluSIon
Emergence plant molecular farming fanfares the potential 
of protein therapeutics production in plant system in past two 
decades. Even though more than 90 per cent of plant-based 
protein production is from stable transgenics, transient gene 
expression by agroinfiltration is more prominent by means of 
its rapidness, safe, economical and reproducibility in nature. 
High expression construct design with viral deconstructive 
approach ‘magnifection technology’ and use of viral 
regulatory pro vector systems are noticeable milestones in the 
plant molecular farming field. On the other hand selection of 
suitable plant hosts system also the important parameter which 
reinforces the absolute yield of the PT, while food crops should 
be avoided to address bio-safety related concerns. Even though 
the system has many advantages, still it has some latent issues 
like post-translational modification (PTM) and other biosafety 
and ethical issues will hinder the commercialisation potential. 
Biosafety like hurdles may be overcome by good manufacturing 
practices, and PTM is the major concern need to be addressed 
to produce humanised therapeutics by glycoengineering, which 
will mimic the mammalian proteins.
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